IMMUNOTHERAPY

Treatment of patients with advanced or metastatic cancers with the transforming growth factor-β receptor type 1 inhibitor LY3200882 demonstrated a tolerable safety profile and early signs of efficacy, according to the results from a first-in-human, dose-escalation phase I trial presented at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer.

Patients with advanced alveolar soft part sarcoma demonstrated durable responses that occurred early following the initiation of atezolizumab, according to phase II trial findings presented at the 2018 CTOS Annual Meeting. Atezolizumab was also well tolerated and demonstrated a favorable safety profile.

Using durvalumab (Imfinzi) combined with tremelimumab for the frontline treatment of patients with metastatic non–small cell lung cancer did not result in a statistically significant improvement in overall survival compared to standard chemotherapy, according to a press release from AstraZeneca.

Results from a two-part, phase I dose-escalation and -expansion trial involving mogamulizumab in combination with durvalumab or tremelimumab for the treatment of patients with advanced solid tumors demonstrated mild-to-moderate adverse events that were tolerable and manageable, according to Dmitriy Zamarin, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, during his presentation at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer.

In an effort to determine best practices and ensure consistent clinical interpretation of tumor mutational burden assessment for patients with cancer, a group of diagnostic test partners conducted an in silico analysis and found that panel-derived TMB strongly correlated with whole-exome sequencing data provided from The Cancer Genome Atlas. 

Personalized immunotherapy regimens for patients with cancer is a long-term goal of the immuno-oncology field, yet progress toward this goal necessitates the discovery of an effective biomarker for guiding treatment decision making, according to Jason Luke, MD. 

According to first-in-human findings reported in a poster presentation during the ESMO Annual Congress, genetically engineered T-cells targeting melanoma-associated antigen-A4 appeared safe and demonstrated some evidence of antitumor activity.

Both&nbsp;progression-free survival and overall response were improved in patients with&nbsp;<em>MET</em> mutated <em>EGFR</em>-positive non&ndash;small cell lung cancer resistant to prior EGFR TKI therapy who were treated with&nbsp;tepotinib plus gefitinib compared with chemotherapy. These phase II findings were presented at the&nbsp;2018 ESMO Congress.

Results from the phase III IMpower130 trial demonstrated a statistically significant improvement in both progression-free survival and overall survival with a triplet regimen of&nbsp;atezolizumab, carboplatin, and nab-paclitaxel compared with chemotherapy alone in patients with previously untreated stage IV nonsquamous non&ndash;small cell lung cancer.

Three months have been added on by the FDA to the review period for the supplemental biologics license application for the frontline treatment combination of nivolumab plus low-dose ipilimumab for patients with advanced non&ndash;small cell lung cancer with tumor mutational burden &ge;10 mutations per megabase.

The combination of atezolizumab and nab-paclitaxel demonstrated a 2.5-month benefit in progression-free survival over nab-paclitaxel alone in&nbsp;patients with PD-L1&ndash;positive metastatic triple-negative breast cancer, according to findings of the phase III IMpassion130 trial presented at the 2018 ESMO Congress.

Brian Rini, MD, professor of medicine, Cleveland Clinic, discusses subgroup findings from the IMmotion151 trial in metastatic renal cell carcinoma.&nbsp;

Investigators have long known that the combination of antiangiogenic agents and immunotherapy could enhance antitumor response and improve outcomes for patients with certain cancers. But recently, this old idea has become the focus of new research in diseases such as hepatocellular carcinoma, urothelial carcinoma, and endothelial cancer.

The role of&nbsp;tumor-infiltrating lymphocytes (TILs) is expanding in cancer care, necessitating a more involved role for pathologists to quantify immune infiltrates,&nbsp;K.P. Siziopikou, MD, PhD, suggested during a presentation at&nbsp;the 2018 Lynn Sage Breast Cancer Symposium.

Justin F. Gainor, MD, assistant professor of medicine, Harvard Medical School, Massachusetts General Hospital, discusses the treatment landscape of oncogenic driver-positive NSCLC.

Alexander Drilon, MD, clinical director of Early Drug Development Service at Memorial Sloan Kettering Cancer Center, discusses the evolving role of immune-checkpoint blockade in NSCLC.

Lung and bronchus cancer are the leading causes of cancer-related deaths in the United States and will be responsible for an estimated 154,050 American deaths in 2018. An estimated 234,030 new cases of lung and bronchus cancer will be diagnosed in 2018, which represents 13.5% of all new cancer diagnoses in the United States.

In a roundtable discussion at the 2018 International Cancer Immunotherapy Conference, Nobel Prize Winner James P. Allison, MD, and other experts discussed the research that is still necessary to bring immunotherapy response rates to 100%.

Durvalumab (Imfinzi) demonstrated an improvement in overall survival compared with placebo in patients with stage III, unresectable non&ndash;small cell lung cancer who have not progressed following chemoradiotherapy, according to updated findings from the PACIFIC trial recently&nbsp;presented at the 19th World Conference on Lung Cancer and simultaneously published in the <em>New England Journal of Medicine</em>.

The first patient has been dosed in the phase III FIGHT trial investigating bemarituzumab (FPA144) combined with chemotherapy in patients with previously untreated advanced gastric or gastroesophageal junction cancer, according to Five Prime Therapeutics, the developer of the isoform-selective FGF receptor 2b antibody.

Peter O&rsquo;Donnell, MD,&nbsp;discusses the integration of immunotherapy in the treatment paradigm of advanced bladder cancer and its potential role as combination therapy.

Hassane M. Zarour, MD, discusses the addition of antibiotics to immunotherapy treatment in patients with melanoma.&nbsp;

Immune checkpoint inhibitor-related toxic events led to deaths in 0.3% to 1.3% of patients, a rate that compares favorably with other treatment modalities, according to results from a retrospective analysis of data collected in Vigilyze, the World Health Organization&rsquo;s pharmacovigilance database.

Bruno Sangro, MD,&nbsp;discusses the current landscape for systemic therapies, new directions with immunotherapy, and the need for greater research into combination therapies for HCC.

James P. Allison, PhD, and Tasuku Honjo, MD, PhD, have been awarded the 2018 Nobel Prize in Physiology or Medicine for their pioneering research that led to the use of immune checkpoint inhibitors in the treatment of cancer. The award was announced in a statement from the Nobel Assembly at Karolinska Institutet on Monday.

Jeffrey S. Weber, MD, PhD,&nbsp;discusses the promise of nivolumab in patients with&nbsp;high-risk resected stage III/IV melanoma and gives a general overview of the melanoma treatment landscape.

Enhanced clinical benefit may be derived from the combination of&nbsp;entinostat and pembrolizumab (Keytruda) in a subgroup of patients&nbsp;with PD-1/PD-L1&ndash;refractory non&ndash;small cell lung cancer who have high levels of peripheral blood monocytes, ongoing analyses suggest.&nbsp;

Matthew Powell, MD, discusses the promise of immunotherapy in ovarian cancer, despite its challenges.

The FDA now requires use of an approved companion diagnostic test to determine PD-L1 levels in the tumor tissue of cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer prescribed treatment with pembrolizumab (Keytruda) or atezolizumab (Tecentriq).

In an interview with <em>Targeted Oncology</em><em>,</em> Levy discusses the agents currently being investigated for patients with <em>ROS1</em>- or <em>TRK</em>-rearranged lung cancer. He also highlights the challenges physicians will need to overcome to best treat their patients based on these new findings.